0KF3: Palatin Technologies, Inc. - Summary | Jitta

Palatin Technologies, Inc.

LON:0KF3

Price
$14.58
Loss Chance
54.1%
2.08JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
658 / 877
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (45)
Recent Business Performance (72)
Financial Strength (33)
Return to Shareholders (3)
Competitive Advantage (40)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningRevenue loss detected in 2021
Operating MarginInconsistent
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.08
100.00%
1.97
101.42%
3.24
122.59%
Biotechnology
0.34
100.00%
1.46
100.00%
2.46
100.00%
COMPANY DESCRIPTION
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.